Calling all diagnostics innovators: A competition for you! If you have an interesting idea or marker for a new diagnostic test then enter the GE European Whatman Dx competition co-sponsored by Mologic. The winner will receive a 3 day coaching engagement with renowned [...]
NEW YORK (360Dx) – British diagnostics company Mologic has completed development of a next-generation lateral flow testing platform that it claims improves sensitivity significantly. The Bedford, UK-based firm is also working with a new center in Dakar, Senegal, that will deploy new tests based on the platform to support [...]
Visually-read device delivers up to 1,000-fold improvement in sensitivity to support surveillance and elimination efforts of global epidemics Since 2016, the Bill & Melinda Gates Foundation has committed $9.7 million to establish and accelerate the CARD technology programme Bedfordshire, UK, 7 May 2019: Mologic Ltd, a leading developer of [...]
Strengthens team as part of continued international expansion Bolsters US presence with the opening of subsidiary in Boston, MA Doubles device manufacturing capacity in UK Bedfordshire, UK, 1 April 2019: Mologic Ltd, a leading developer of lateral flow and rapid diagnostic technologies, services and products, today announced it has [...]
Today the Foundation for Innovative New Diagnostics (FIND) is leading a consortium, of which Mologic is part, announced the launch of a new schistosomiasis programme within its neglected tropical disease portfolio. FIND is leading a consortium which along with the WHO is developing novel rapid diagnostic tests for schistosomiasis infection that affects over 206 million people across 78 tropical and sub-tropical countries
In a recent interview with 360Dx, Mark Davis discussed how Mologic continues to develop it’s strong pipeline of rapid POC diagnostics and begins to look into the North American market for expansion and strategic partners... NEW YORK (360Dx) – Mologic is expanding into the US market and targeting the near-term commercialization of rapid [...]
Bedfordshire, UK, 02 August 2018: Mologic Ltd, a developer of powerful, personalised diagnostics to improve the lives of patients, today announced that it has commenced a clinical trial to evaluate the Company’s urine-based diagnostic, HeadsUp, in monitoring pulmonary exacerbation in cystic fibrosis (CF) patients. The study aims to identify five [...]
The Foundation for Innovative New Diagnostics (FIND) announced last Friday that it has awarded grants to a number of companies to address the urgent diagnostic needs for hepatitis C virus (HCV). These grants will be used to conduct feasibility studies of various technologies that could transform HCV testing at [...]
GSK and Medicines for Malaria Venture (MMV) today announced that the United States Food and Drug Administration (FDA) has approved, under Priority Review, single-dose Krintafel(tafenoquine) for the radical cure (prevention of relapse) of Plasmodium vivax (P. vivax) malaria in patients aged 16 years and older who are receiving appropriate antimalarial therapy for acute P. vivax infection. Read [...]
Mologic and Newcastle University launch BReD diagnostic for blackgrass resistance at Cereals Bedfordshire and Newcastle, UK, 13 June 2018: Mologic Ltd, a developer of personalised diagnostics, and Newcastle University, today announced they have developed an on-farm blackgrass resistance diagnostic (BReD). The one-step, rapid lateral flow product for detecting glutathione transferase (AmGSTF1) [...]
